DeepMed Research

VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Phase 1

Terminated

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-955176, Moxifloxacin, Placebo (Part 2)
Drug: BMS-955176, Placebo (Part 1)

First Posted Date: 2015-10-15

Last Posted Date: 2017-08-09

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 315

Registration Number: NCT02576119

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: ABC/DTG/3TC FDC tablet

First Posted Date: 2015-09-03

Last Posted Date: 2015-12-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 12

Registration Number: NCT02539576

Locations: 🇺🇸
GSK Investigational Site, Glendale, California, United States

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068

First Posted Date: 2015-07-24

Last Posted Date: 2017-09-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 27

Registration Number: NCT02508064

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068
Drug: Oral Contraceptive
Drug: Loestrin 1.5/30

First Posted Date: 2015-06-25

Last Posted Date: 2017-07-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 26

Registration Number: NCT02480881

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068
Drug: Maraviroc

First Posted Date: 2015-06-25

Last Posted Date: 2017-09-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 112

Registration Number: NCT02480894

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Subjects do not receive study medication in this study 202094

First Posted Date: 2015-06-23

Last Posted Date: 2020-10-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 102

Registration Number: NCT02478632

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Cabotegravir tablet 30 mg once daily for 28 days.
Drug: Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

First Posted Date: 2015-06-23

Last Posted Date: 2020-06-22

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 19

Registration Number: NCT02478463

Locations: 🇺🇸
GSK Investigational Site, Pittsburgh, Pennsylvania, United States

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: BMS-663068

First Posted Date: 2015-06-10

Last Posted Date: 2017-09-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 52

Registration Number: NCT02467335

Locations: 🇺🇸
GSK Investigational Site, Hamilton, New Jersey, United States

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: CAR
Drug: DTG 50 mg
Drug: RPV 25 mg

First Posted Date: 2015-04-29

Last Posted Date: 2023-11-28

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 510

Registration Number: NCT02429791

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: CAR
Drug: DTG 50 mg
Drug: RPV 25 mg

First Posted Date: 2015-04-21

Last Posted Date: 2023-11-28

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 518

Registration Number: NCT02422797

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy